Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Colorectal Neoplasms 14Rectal Neoplasms 13Colonic Neoplasms 10Esophageal Neoplasms 5Stomach Neoplasms 4Rhabdomyosarcoma 4Pancreatic Neoplasms 4Neuroblastoma 4Central Nervous System Neoplasms 4Adenocarcinoma Of Esophagus 4Sarcoma 3Neoplasm Metastasis 3Medulloblastoma 3Lung Neoplasms 3Wilms Tumor 2Unspecified Childhood Solid Tumor, Protocol Specific 2Sarcoma, Ewing 2Ovarian Neoplasms 2Optic Nerve Glioma 2Oligodendroglioma 2Malignant mesenchymal tumor 2Fibrolamellar hepatocellular carcinoma 2Familial ependymoma 2Esophageal Squamous Cell Carcinoma 2Choroid Plexus Neoplasms 2Astrocytoma 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Stage I Mixed Cell Type Kidney Wilms Tumor 1

Interventions

Platinum 4Cisplatin 4Carboplatin 31,2-diaminocyclohexaneplatinum II citrate 3regorafenib 2pegfilgrastim 2Radiotherapy, Intensity-Modulated 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Docetaxel 2Bevacizumab 2trifluridine tipiracil drug combination 1pembrolizumab 1merphos 1dehydroftorafur 1X-Rays 1Vinblastine 1Trifluridine 1Taxes 1Specimen Handling 1Radiotherapy, Image-Guided 1Radiotherapy 1Radiation 1Nivolumab 1Nephroureterectomy 1N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 1Methotrexate 1Irinotecan 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Carcinoma × Irinotecan × Clear all
NCT04879368 2025-07-17

INTEGRATEIIb

Australasian Gastro-Intestinal Trials Group

Phase 3 Active not recruiting
450 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡